韦里西瓜特通过NO/cGMP/PKG通路改善了与CKD相关的血管化
Chengsi Li1, Jing Li1, Chengyingjie Yang1
1Department of Cardiology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, No. 1665, Kongjiang Road, Shanghai 200000, China.
International immunopharmacology
|February 22, 2026
概括
维里西瓜特是一种可溶性瓜尼环酶敏感剂,通过激活NO/cGMP/PKG通路,有效地治疗慢性病 (CKD) 中的血管化. 这一发现为高心血管风险的CKD患者提供了新的治疗途径.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性病 (CKD) 导致功能逐渐丧失.
- 血管化是一种常见的CKD并发症,也是心血管事件的预测因素.
- 溶性瓜尼利基环酶 (sGC) 敏感剂代表了一个潜在的治疗策略.
研究的目的:
- 为了研究 vericiguat (VER) 在减弱CKD相关的血管化的机制.
- 为了验证VER是否可以缓解由于和代谢而导致的sGC活性下降.
- 探索NO/cGMP/PKG途径在VER治疗效果中的作用.
主要方法:
- 结核病相关的血管化的体外和体外实验模型.
- 评估水平,骨质生成标志物,eNOS和PKG表达.
- 测量氧化 (NO) 和循环氨酸单酸盐 (cGMP) 的水平.
- 使用L-NAME来对抗VER效应的抑制研究.
主要成果:
- 增加的水平和骨质原生标志物的上调被观察到CKD大鼠大动脉和VSMCs.
- 韦里西瓜特通过激活NO/cGMP/PKG通路,显著改善了化.
- L-NAME逆转了 vericiguat 的有益影响,证实了途径的参与.
结论:
- 在CKD模型中,Vericiguat有效地减轻了血管化.
- vericiguat的治疗效果通过NO/cGMP/PKG通路进行介导.
- 韦里西瓜特在治疗慢性病患者的血管并发症方面表现有前途.
相关概念视频
Antihypertensive Drugs: Vasodilators
2.3K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.3K
Antihypertensive Drugs: Action of Calcium Channel Blockers
1.9K
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
1.9K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.6K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.6K
Nitric Oxide Signaling Pathway
6.4K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
6.4K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
649
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
649
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
591
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
591


